Sector
PharmaceuticalsOpen
₹115Prev. Close
₹115.27Turnover(Lac.)
₹173.6Day's High
₹116.86Day's Low
₹113.552 Week's High
₹131.452 Week's Low
₹89.5Book Value
₹48.01Face Value
₹10Mkt Cap (₹ Cr.)
555.47P/E
38.25EPS
3.02Divi. Yield
0Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 48.73 | 48.73 | 16.24 | 16.24 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 183.23 | 145.45 | 153.86 | 140.81 |
Net Worth | 231.96 | 194.18 | 170.1 | 157.05 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Revenue | 303.62 | 274.31 | 271.89 | 235.01 |
yoy growth (%) | 10.68 | 0.89 | 15.69 | -12.4 |
Raw materials | -158.63 | -143.13 | -140.88 | -119.96 |
As % of sales | 52.24 | 52.17 | 51.81 | 51.04 |
Employee costs | -34.48 | -50.61 | -40.8 | -32.99 |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Profit before tax | 13.76 | -1.48 | 18.25 | 17.57 |
Depreciation | -14.61 | -13.27 | -9.78 | -9.02 |
Tax paid | -2.96 | 3.22 | -5.82 | 1.08 |
Working capital | 6.4 | 3.92 | -1.98 | 0.76 |
Other operating items |
Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 10.68 | 0.89 | 15.69 | -12.4 |
Op profit growth | 86.08 | -41.75 | 7.58 | 7.94 |
EBIT growth | 120.7 | -59.53 | 0.71 | 12.31 |
Net profit growth | 222.65 | -90.48 | -2.02 | 262.77 |
Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
---|---|---|---|---|---|
Gross Sales | 367.42 | 398.53 | 333.43 | 307.26 | 277.74 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 367.42 | 398.53 | 333.43 | 307.26 | 277.74 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 5.18 | 6.41 | 4.4 | 2.34 | 4.52 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,809.95 | 157.48 | 4,34,147.67 | 863.29 | 0.75 | 5,123.67 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 5,932.6 | 85.72 | 1,57,464.02 | 518 | 0.5 | 2,302 | 513.62 |
Cipla Ltd CIPLA | 1,455.2 | 27.77 | 1,17,560.12 | 1,178.16 | 0.89 | 3,969.86 | 360.73 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,350 | 69.27 | 1,13,318.29 | 460 | 0.84 | 2,376 | 222.38 |
Mankind Pharma Ltd MANKIND | 2,666.4 | 53.34 | 1,06,926.71 | 634.43 | 0 | 2,529.74 | 269.23 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Managing Director
Anwar S Daud
Director (Finance)
Zulfiquar M Kamal
Director (Operation)
Prakash Sapkal
Director (Business Developmnt)
Niraj Dhadiwal
Non-Exec. & Independent Dir.
Kavita Loya
Non-Exec. & Independent Dir.
Padmakar Joshi
Company Sec. & Compli. Officer
Piyush Nikhadi
Independent Director
Kamlesh Shende
Independent Director
Kakasaheb Mahadik
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Zim Laboratories Ltd
Summary
Zim Laboratories Ltd was incorporated in February, 1984 under the name and style of Zim Laboratories Private Limited in the State of Maharashtra. The Company became a Public Limited Company through fresh Certificate of Incorporation issued by the Registrar of Companies, Maharashtra, Mumbai. The Company is engaged in the manufacturing of formulation on drugs and pre formulation ingredients in India and marketing and selling these within and outside India. The Pharma Industry is dominated by Multinationals, Large Indian companies and in the lower end of the market large number of units mainly in the SSI sector.During the year 2019-20, ZIM Health Technologies Limited was acquired thereby resulting as a wholly owned subsidiary of the company . SIA ZIM Laboratories Limited got incorporated as a wholly owned subsidiary in Latvia.In 2023, the Company launched Thinoral (Patented Oral Thin Film technology) as an alternate drug delivery platform across RoW/Pharmerging Markets and EU.
Read More
The Zim Laboratories Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹114 today.
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Zim Laboratories Ltd is ₹555.47 Cr. as of 11 Dec ‘24
The PE and PB ratios of Zim Laboratories Ltd is 38.25 and 2.40 as of 11 Dec ‘24
The 52-week high/low is the highest and lowest price at which a Zim Laboratories Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Zim Laboratories Ltd is ₹89.5 and ₹131.4 as of 11 Dec ‘24
Zim Laboratories Ltd's CAGR for 5 Years at N/I%, 3 Years at 0.92%, 1 Year at 3.80%, 6 Month at 9.06%, 3 Month at -2.24% and 1 Month at 7.62%.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
Invest wise with Expert advice